Terms: = Bone cancer AND NSD1, FLJ44628, 64324, ENSG00000165671, Q96L73, FLJ22263, DKFZp666C163, ARA267, STO, SOTOS AND Prognosis
3 results:
1. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia.
Abla O; Ries RE; Triche T; Gerbing RB; Hirsch B; Raimondi S; Cooper T; Farrar JE; Buteyn N; Harmon LM; Wen H; Deshpande AJ; Kolb EA; Gamis AS; Aplenc R; Alonzo T; Meshinchi S
Blood Adv; 2024 Apr; 8(8):2005-2017. PubMed ID: 38306602
[TBL] [Abstract] [Full Text] [Related]
2. Dasatinib and navitoclax act synergistically to target NUP98-nsd1
Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
[TBL] [Abstract] [Full Text] [Related]
3. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
Struski S; Lagarde S; Bories P; Puiseux C; Prade N; Cuccuini W; Pages MP; Bidet A; Gervais C; Lafage-Pochitaloff M; Roche-Lestienne C; Barin C; Penther D; Nadal N; Radford-Weiss I; Collonge-Rame MA; Gaillard B; Mugneret F; Lefebvre C; Bart-Delabesse E; Petit A; Leverger G; Broccardo C; Luquet I; Pasquet M; Delabesse E
Leukemia; 2017 Mar; 31(3):565-572. PubMed ID: 27694926
[TBL] [Abstract] [Full Text] [Related]